Syngene International quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	833	911	−8.6%
EBITDA	147	200	−26.1%
EBITDA margin	17.7%	21.9%	−4.2 pts
Profit before tax	47.0	85.2	−44.8%
Net profit	32.2	67.1	−52.0%
EPS	₹0.80	₹1.67	−52.1%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	833	736	1,037	917	911	875	1,018	944	891	790	917	854	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	28.0	25.3	22.2	15.4	15.4	17.7	18.9	18.3	16.5	18.1	16.1	29.3
	861	761	1,059	933	926	892	1,037	962	908	808	933	883
	203	178	223	221	228	240	228	242	231	168	172	240
	−4.4	−4.8	9.8	8.5	11.0	−21.9	6.9	−4.5	5.8	65.5	30.7	−2.9
	273	259	301	267	275	262	253	250	252	230	227	221
	10.0	9.6	12.1	11.9	13.2	11.6	15.9	12.4	13.1	11.7	12.9	10.8
	112	112	112	114	117	111	106	109	111	107	111	108
	214	213	199	211	198	189	186	173	158	157	170	164
	807	767	857	834	841	791	796	781	770	739	724	741
	147	90.8	303	209	200	206	344	284	245	170	317	232
	35.7	−21.4	192	95.5	83.0	95.2	238	175	134	62.9	206	123
Profit
	53.7	−5.7	202	99.0	85.2	101	241	181	137	69.3	209	142
	−6.7	−13.5	−6.0	−70.6	0.0	0.0	0.0	0.0	0.0	32.0	0.0	−3.7
	47.0	−19.2	196	28.4	85.2	101	241	181	137	101	209	138
	9.4	0.1	35.6	10.9	17.7	22.8	46.9	44.9	27.4	19.2	42.4	24.5
	5.4	−10.3	12.5	2.5	0.4	−8.2	10.3	4.8	3.8	6.4	−22.0	2.2
	14.8	−10.2	48.1	13.4	18.1	14.6	57.2	49.7	31.2	25.6	20.4	26.7
	32.2	−9.0	148	15.0	67.1	86.7	183	131	106	75.7	189	112
	32.2	−9.0	148	15.0	67.1	86.7	183	131	106	75.7	189	112
	10.7	35.3	−85.7	7.1	−139	21.4	55.4	−56.9	−40.3	27.1	40.9	20.6
	42.9	26.3	62.2	22.1	−71.7	108	239	74.2	65.8	103	230	132
	—	—	148	—	67.1	86.7	183	131	—	—	—	—
Per share
	₹0.80	−₹0.22	₹3.68	₹0.37	₹1.67	₹2.16	₹4.56	₹3.27	₹2.64	₹1.89	₹4.70	₹2.78
	₹0.80	−₹0.22	₹3.67	₹0.37	₹1.67	₹2.15	₹4.56	₹3.26	₹2.64	₹1.88	₹4.69	₹2.77
Other comprehensive income — detail
	10.7	35.3	−85.7	7.1	−139	21.4	55.4	—	—	—	—	—
	−2.3	−0.6	1.3	−2.5	−5.4	0.3	6.8	−1.9	−3.2	1.2	−8.9	−1.0
	−0.3	−0.2	0.3	−0.6	−1.4	0.1	1.9	—	—	—	—	—
	—	—	—	—	—	—	—	−0.4	−1.1	0.5	−3.3	−0.2
	14.2	47.8	−118	10.4	−189	28.7	69.7	−73.3	−51.8	34.3	71.2	27.3
	1.5	12.1	−31.3	1.4	−54.2	7.5	19.2	—	—	—	—	—
	—	—	—	—	—	—	—	−17.9	−13.6	7.9	24.7	5.9
Per share — as-filed variants
	₹0.80	−₹0.22	₹3.68	₹0.37	₹1.67	₹2.16	₹4.56	₹3.27	₹2.64	₹1.89	₹4.70	₹2.78
	₹0.80	−₹0.22	₹3.67	₹0.37	₹1.67	₹2.15	₹4.56	₹3.26	₹2.64	₹1.88	₹4.69	₹2.77
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	634	563	803	688	672	657	783	706	654	556	714	616
	76.1%	76.4%	77.5%	75.0%	73.8%	75.1%	76.9%	74.8%	73.4%	70.4%	77.9%	72.2%
Adjusted (ex-exceptional items) — derived
	53.7	−5.7	202	99.0	85.2	101	241	181	137	69.3	209	142
	−6.7	−13.5	−6.0	−70.6	0.0	0.0	0.0	0.0	0.0	32.0	0.0	−3.7
	36.8	−2.7	152	52.3	67.1	86.7	183	131	106	51.8	189	114
	₹0.91	−₹0.07	₹3.79	₹1.29	₹1.67	₹2.16	₹4.56	₹3.27	₹2.64	₹1.29	₹4.70	₹2.85

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNGENE₹398.60

Syngene International Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSAILIFE DIVISLAB WOCKPHARMA GLAND ASTERDM PPLPHARMA COHANCE LALPATHLABMcap ₹16,060 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	853.5	916.9	789.7	891.0	943.7	1,018.0	874.5	910.6	917.1	1,036.5	736.0	832.7
Other Income	29.3	16.1	18.1	16.5	18.3	18.9	17.7	15.4	15.4	22.2	25.3	28.0
Total Income	882.8	933.0	807.8	907.5	962.0	1,036.9	892.2	926.0	932.5	1,058.7	761.3	860.7
Expenses
+ Cost of Materials Consumed	240.3	172.1	168.0	230.8	241.9	228.1	239.5	227.5	220.9	223.3	178.2	203.0
+ Changes in Inventories	-2.9	30.7	65.5	5.8	-4.5	6.9	-21.9	11.0	8.5	9.8	-4.8	-4.4
+ Employee Benefit Expense	220.9	226.9	229.9	251.5	249.5	253.0	261.7	275.0	267.4	300.8	259.1	272.7
+ Finance Costs	10.8	12.9	11.7	13.1	12.4	15.9	11.6	13.2	11.9	12.1	9.6	10.0
+ Depreciation & Amortisation	108.1	111.1	106.9	110.9	108.7	106.1	111.2	116.5	113.7	111.5	112.2	111.7
+ Other Expenses	163.7	170.3	156.5	158.1	173.2	186.4	188.8	197.6	211.1	199.2	212.7	214.0
Total Expenses	740.9	724.0	738.5	770.2	781.2	796.4	790.9	840.8	833.5	856.7	767.0	807.0
EBITDA	231.5	316.9	169.8	244.8	283.6	343.6	206.4	199.5	209.2	303.4	90.8	147.4
EBIT	123.4	205.8	62.9	133.9	174.9	237.5	95.2	83.0	95.5	191.9	-21.4	35.7
Profit
PBT before Exceptional Items	141.9	209.0	69.3	137.3	180.8	240.5	101.3	85.2	99.0	202.0	-5.7	53.7
+ Exceptional Items	-3.7	0.0	32.0	0.0	0.0	0.0	0.0	0.0	-70.6	-6.0	-13.5	-6.7
Pretax Income	138.2	209.0	101.3	137.3	180.8	240.5	101.3	85.2	28.4	196.0	-19.2	47.0
+ Current Tax	24.5	42.4	19.2	27.4	44.9	46.9	22.8	17.7	10.9	35.6	0.1	9.4
+ Deferred Tax	2.2	-22.0	6.4	3.8	4.8	10.3	-8.2	0.4	2.5	12.5	-10.3	5.4
Tax Expense	26.7	20.4	25.6	31.2	49.7	57.2	14.6	18.1	13.4	48.1	-10.2	14.8
Net Income	111.5	188.6	75.7	106.1	131.1	183.3	86.7	67.1	15.0	147.9	-9.0	32.2
+ Net Income — Continuing Ops	111.5	188.6	75.7	106.1	131.1	183.3	86.7	67.1	15.0	147.9	-9.0	32.2
+ Other Comprehensive Income	20.6	40.9	27.1	-40.3	-56.9	55.4	21.4	-138.8	7.1	-85.7	35.3	10.7
Total Comprehensive Income	132.1	229.5	102.8	65.8	74.2	238.7	108.1	-71.7	22.1	62.2	26.3	42.9
Net Income to Common	—	—	—	—	131.1	183.3	86.7	67.1	—	147.9	—	—
Per Share
Basic EPS	2.78	4.70	1.89	2.64	3.27	4.56	2.16	1.67	0.37	3.68	-0.22	0.80
Diluted EPS	2.77	4.69	1.88	2.64	3.26	4.56	2.15	1.67	0.37	3.67	-0.22	0.80
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	55.4	21.4	-138.8	7.1	-85.7	35.3	10.7
+ Items NOT to be Reclassified to P&L	-1.0	-8.9	1.2	-3.2	-1.9	6.8	0.3	-5.4	-2.5	1.3	-0.6	-2.3
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	1.9	0.1	-1.4	-0.6	0.3	-0.2	-0.3
+ Tax on Items NOT to be Reclassified — alt tag	-0.2	-3.3	0.5	-1.1	-0.4	—	—	—	—	—	—	—
+ Items to be Reclassified to P&L	27.3	71.2	34.3	-51.8	-73.3	69.7	28.7	-189.0	10.4	-118.0	47.8	14.2
+ Tax on Items to be Reclassified	—	—	—	—	—	19.2	7.5	-54.2	1.4	-31.3	12.1	1.5
+ Tax on Items to be Reclassified — alt tag	5.9	24.7	7.9	-13.6	-17.9	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.78	4.70	1.89	2.64	3.27	4.56	2.16	1.67	0.37	3.68	-0.22	0.80
Diluted EPS — Continuing Operations	2.77	4.69	1.88	2.64	3.26	4.56	2.15	1.67	0.37	3.67	-0.22	0.80
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	616.1	714.1	556.2	654.4	706.3	783.0	656.9	672.1	687.7	803.4	562.6	634.1
Gross Margin %	72.19	77.88	70.43	73.45	74.84	76.92	75.12	73.81	74.99	77.51	76.44	76.15
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	141.9	209.0	69.3	137.3	180.8	240.5	101.3	85.2	99.0	202.0	-5.7	53.7
− Exceptional Items (reconciliation)	-3.7	0.0	32.0	0.0	0.0	0.0	0.0	0.0	-70.6	-6.0	-13.5	-6.7
Net Income Adj (tax-effected)	114.5	188.6	51.8	106.1	131.1	183.3	86.7	67.1	52.3	152.4	-2.7	36.8
EPS Adj	2.85	4.70	1.29	2.64	3.27	4.56	2.16	1.67	1.29	3.79	-0.07	0.91
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	402.0	402.0	402.5	402.5	402.5	402.5	402.9	402.9	402.9	402.9	403.7	403.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Syngene International Q2 FY27 results (July–September 2026)

Filed with NSE on Tuesday, 27 October 2026 at 7:35 pm IST

Syngene International (NSE: SYNGENE) reported its Q2 FY27 results (July–September 2026) on Tuesday, 27 October 2026 at 7:35 pm IST. Consolidated net profit was ₹32.2 crore, down 52.0% from ₹67.1 crore in Q2 FY26 and against a loss of ₹9 crore in Q1 FY27. Revenue from operations was ₹833 crore, down 8.6% year on year and up 13.1% from the previous quarter.

Q2 FY26 results (a year earlier): 5 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹32.2 Cr−52.0% vs Q2 FY26loss ₹9 Cr in Q1 FY27
Revenue from operations: ₹833 Cr−8.6% vs Q2 FY26+13.1% vs Q1 FY27
Operating margin (EBIT): 4.3%−4.8 pts vs Q2 FY26+7.2 pts vs Q1 FY27EBIT ₹35.7 Cr
EBITDA: ₹147 Cr−26.1% vs Q2 FY26+62.3% vs Q1 FY27margin 17.7%
Earnings per share (basic): ₹0.80−52.1% vs Q2 FY26
Net profit margin: 3.9%−3.5 pts vs Q2 FY26+5.1 pts vs Q1 FY27

Questions

What was Syngene International's net profit in Q2 FY27?

Consolidated net profit was ₹32.2 crore, down 52.0% from ₹67.1 crore in Q2 FY26 and against a loss of ₹9 crore in Q1 FY27.

What was Syngene International's revenue in Q2 FY27?

Revenue from operations was ₹833 crore, down 8.6% year on year and up 13.1% from the previous quarter.

How were Syngene International's Q2 FY27 results?

Both fell from a year earlier: net profit was down 52.0% at ₹32.2 crore and revenue was down 8.6% at ₹833 crore. The operating margin was 4.3%, down 4.8 percentage points from 9.1% a year earlier.

What was Syngene International's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹35.7 crore, a margin of 4.3%, against −2.9% in Q1 FY27 and 9.1% in Q2 FY26. EBITDA was ₹147 crore, 17.7% of revenue.

What was Syngene International's net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹23.2 crore, down 84.9% from ₹154 crore in the same months a year earlier. Revenue from operations was ₹1,569 crore, down 12.1%.

What is Syngene International's net profit margin?

Syngene International's net profit margin was 3.9% in Q2 FY27 (net profit as a share of revenue from operations), against 7.4% in Q2 FY26 (down 3.5 percentage points). For FY26 as a whole it was 8.5%.

What was Syngene International's EPS in Q2 FY27?

Basic earnings per share were ₹0.80, against ₹1.67 in Q2 FY26.

What was Syngene International's net profit in FY26?

Consolidated net profit was ₹317 crore in FY26 (April 2025–March 2026), down 36.2% from ₹496 crore in FY25. It was ₹510 crore in FY24 and ₹464 crore in FY23: down 31.8% over three years, an average fall of 12.0% a year.

When did Syngene International announce its Q2 FY27 results?

On Tuesday, 27 October 2026 at 7:35 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 5 November 2025.

How has Syngene International's profit changed over the last four quarters?

Net profit by quarter: a profit of ₹15 crore in Q3 FY26, a profit of ₹148 crore in Q4 FY26, a loss of ₹9 crore in Q1 FY27 and a profit of ₹32.2 crore in Q2 FY27. That is a combined profit of ₹186 crore over the four quarters, down 60.3% from ₹468 crore in the four quarters before. Revenue from operations: ₹917 crore, ₹1,037 crore, ₹736 crore and ₹833 crore.

What was Syngene International's revenue in FY26?

Revenue from operations was ₹3,739 crore in FY26 (April 2025–March 2026), up 2.6% from ₹3,642 crore in FY25. It was ₹3,489 crore in FY24 and ₹3,193 crore in FY23: up 17.1% over three years, 5.4% a year on average.

When will Syngene International announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Syngene International figures come from?

From Syngene International's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 27 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.